US stock market abnormal movement | BeiGene (ONC.US) rose more than 3%, with a 55% year-on-year increase in revenue in 2024.

According to the Wisdom Financial APP, on Wednesday, BeiGene (BEI.US) rose more than 3%, reaching $259. The financial report shows that BeiGene achieved total revenues of approximately $3.81 billion in 2024, a year-on-year increase of about 55%; product revenue increased by about 72.6% year-on-year to approximately $3.8 billion. Gross profit was approximately $3.216 billion, an increase of 54.71% year-on-year. The company's full-year performance achieved strong growth, benefiting from the continued success of BeiYueze and one of the richest solid tumor pipelines developed by the company in the field of oncology. It is expected that multiple projects will have data readouts by 2025.